Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Takeda (Details)

v3.22.1
Licensing and Other Arrangements - Takeda (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
Nov. 16, 2016
Nov. 01, 2006
Feb. 28, 2009
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Licensing and other arrangements            
Revenue from contracts with customers       $ 2,750 $ 19  
Takeda | Collaboration agreement            
Licensing and other arrangements            
Revenue from contracts with customers $ 2,000     800 $ 0  
Contract assets       0   $ 0
Contract liabilities       0   0
Capitalized contract costs       0   $ 0
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones       $ 16,000    
Takeda | Collaboration agreement | TAK-079            
Licensing and other arrangements            
Royalty payment period   13 years 6 months        
Royalty payment period from the first commercial sale of each royalty-bearing discovery product   12 years        
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones   $ 19,000        
Takeda | Collaboration agreement | Other antibodies            
Licensing and other arrangements            
Maximum eligible milestone payments receivable per discovery product candidate     $ 3,300      
Royalty payment period     10 years